Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT07596901 · tracked via the Priya Life Science USA tracker

Sponsor

Aurinia Pharmaceuticals Inc.

Phase

Phase 1/2

Started

2026-04-22

Last updated

2026-08-03

Condition(s) studied

Myasthenia Gravis, Generalized

Investigational drug(s) / intervention(s)

AritinerceptPlacebo

Aritinercept: For subcutaneous injection

Placebo: For subcutaneous injection

Study summary

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeeding or intending to become pregnant during the Study * Additional exclusion criteria are defined in the protocol

Primary outcome measure(s)

To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events — Baseline to study completion, up to 73 weeks

Trial sites (11)

Facility	City	Region	Status
Aurinia Investigational Site	Pasadena	California	Recruiting
Aurinia Investigational Site	Altamonte Springs	Florida	Recruiting
Aurinia Investigational Site	Boca Raton	Florida	Recruiting
Aurinia Investigational Site	Homestead	Florida	Recruiting
Aurinia Investigational Site	Miami	Florida	Recruiting
Aurinia Investigational Site	Miami	Florida	Recruiting
Aurinia Investigational Site	Chicago	Illinois	Recruiting
Aurinia Investigational Site	O'Fallon	Illinois	Recruiting
Aurinia Investigational Site	Dearborn	Michigan	Recruiting
Aurinia Investigational Site	Flint	Michigan	Recruiting
Aurinia Investigational Site	Houston	Texas	Recruiting

More Aurinia Pharmaceuticals Inc. trials in the USA

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis Recruiting

Other trials for the same condition

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Active, not recruiting

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Recruiting

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting

Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis Starting soon

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07596901 on ClinicalTrials.gov ↗ ← All trials in the USA